Company: SMNR
Filing Date: 2025-09-26
Form Type: 8-K
Source: 0001193125-25-220455
Chunk: 1

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-09-26
Form: 8-K
Item: Item 2.03
Chunk 1
---
 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act.

  Item 3.03.      Material Modification to Rights of Security Holders.  

In connection with the Domestication and immediately prior to the consummation of the Business Combination, Denali filed a certificate of incorporation with the Secretary of State of the State of Delaware. The material terms of the certificate of incorporation and the general effect upon the rights of holders of Denali’s capital stock are discussed in the Proxy Statement/Prospectus in the sections titled “ Proposal 2 - The Domestication Proposal” and “Proposals 5A-5G - The” which are incorporated herein by reference.

As disclosed below in Item 8.01, in accordance with Rule12g-3(a)under the Exchange Act, New Semnur is the successor issuer to Denali and has succeeded to the attributes of Denali as the registrant. In addition, the shares of New Semnur Common Stock, as the successor to Denali, are deemed to be registered under Section 12(b) of the Exchange Act.

Restated Certificate of Incorporation of New Semnur and Bylaws of New Semnur

Upon the effectiveness of the Domestication, Denali’s memorandum and articles of association in effect immediately prior to the Domestication were replaced with a certificate of incorporation and bylaws of Denali, which continued in effect through the Closing. In connection with the Closing, Denali changed its corporate name of “ Denali Capital Acquisition Corp.” to “ Semnur Pharmaceuticals, Inc.” and restated its certificate of incorporation (the “ Restated Charter”) to remove provisions relating to the incorporator and initial board of directors following the Domestication and prior to the Effective Time. The bylaws of Denali became the bylaws of New Semnur (the “ Bylaws”). The Restated Charter authorizes the issuance by New Semnur of up to 45,000,000 shares of preferred stock, par value $0.0001 per share, and on September 22, 2025, New Semnur filed a Certificate of Designations designating 5,423,606 shares of such preferred stock of New Semnur as “ Series A Preferred Stock” (the “ Certificate of Designations”). The Certificate of Designations sets forth the powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock. Copies of the Rest